prostate cancer
Algeta to co-promote Alpharadin in US
April 12, 2012Sales and Marketing Algeta, Bayer, prostate cancer
Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …
FDA grants priority review for Sanofi cancer drug
April 5, 2012Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer
The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Prostate cancer drug extends life after chemotherapy
March 29, 2012Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer
Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …
Janssen’s Zytiga launched in the UK
September 21, 2011Sales and Marketing Zytiga, prostate cancer
Janssen’s new advanced prostate cancer treatment Zytiga has been launched in the UK. Zytiga (abiraterone acetate) has been shown in …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
FDA fast tracks Bayer prostate cancer drug
August 23, 2011Sales and Marketing Algeta, Alpharadin, Bayer, prostate cancer
Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …
Janssen’s prostate cancer drug gains European backing
July 26, 2011Sales and Marketing Zytiga, prostate cancer
Janssen’s prostate cancer treatment Zytiga has been recommended by Europe’s CHMP, paving the way for possible third quarter launch. The …
Sanofi launches Jevtana in UK
July 6, 2011Sales and Marketing Jevtana, Sanofi, prostate cancer
Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …
Prostate cancer drug Zytiga gains US approval
May 5, 2011Sales and Marketing Centocor Ortho Biotech, Johnson & Johnson, Zytiga, prostate cancer
Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …
GSK withdraws applications for Avodart
March 25, 2011Research and Development Avodart, Cancer, GSK, bph, prostate cancer
GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …
Sanofi prostate cancer drug Jevtana approved in Europe
March 21, 2011Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer
Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …
Late-stage blow to AstraZeneca’s prostate cancer drug
February 7, 2011Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan
A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Success in pre-clinical microRNA treatment of prostate cancer
January 19, 2011Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai
A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …
Bavarian Nordic courting cancer vaccine backers
November 12, 2010Research and Development, Sales and Marketing Bavarian Nordic, Dendreon, Prostvac, Provenge, TroVax, cancer vaccine, prostate cancer, prostate cancer vaccine, zibotentan
Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
